Experts at the postgraduate Institute of Medical Education and Research (PGIMER) in Chandigarh said that the Mycobacterium w (Mw) vaccine is not a vaccine for Covi-19 and will be used only as an adjunct. The facility was among three premiere health institutes, including AIIMS Delhi, AIIMS Bhopal, are chosen to conduct trials of this Mw vaccine which is normally used for treating leprosy patients.
PGI spokesperson said on Sunday that “We have planned prospective randomized trials to study the effectiveness of Mw in the treatment of hospitalized Covid-19 patients. The Mw vaccine will be used as an adjunct for the patients.”
In a recent trial, it has been founded that MW vaccine reduces mortality of ICU patients with severe sepsis. “Mw can potentially decrease the cytokine storm seen in patients with covid-19 and may thus be a potential benefit in managing these patients and decreasing mortality.” Said the spokesperson.
Citing the recent trail, PGI officials said that the impact of Mw use on long term safety and efficacy will be only known after the conclusion of this CSIR supported the clinical trial. “It is very early to say about the outcome of results and its use.” Said the official.
This trial will study the use of Mycobacterium was an adjunct to the treatment of critically ill covid-19 patients. The officials said that Mycobacterium w originally developed as an immunomodulator for leprosy.
The PGI spokesperson said that “Mw can potentially decrease the cytokine storm seen in patients with Covid-19, and may thus be of potential benefit in managing these patients and decreasing mortality.”
The PGI doctors in the pre-study phase have estimated that the safety of Mw vaccine in four hospitalized patients with Covid-19.